Long-Term Exposure to Fine Particulate Matter and Kidney Function among Patients with Polycystic Kidney Disease
- 14 April 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (7) , 1159-1165
Abstract
Key Points: Long-term exposure to fine particulate matter was associated with faster decline in kidney function among patients with polycystic kidney disease. Associations were stronger in younger patients and those with preserved kidney function at baseline. The association was weaker among patients prescribed tolvaptan. Background: Polycystic kidney disease (PKD) is the fourth leading cause of ESKD. Although the condition is primarily genetic, environmental exposures such as air pollution may influence disease progression. Methods: We investigated whether long-term exposure to fine particulate matter (PM 2 . 5 ) is associated with kidney function decline among individuals with PKD and whether this association differs by age, sex, initial kidney function, and tolvaptan use. Using the Korea National Health Information Database, we identified 18,898 adults with PKD who underwent at least two health screenings between 2016 and 2023. Annual mean PM 2 . 5 exposure was estimated with a high-resolution (1 km 2 ) machine learning–based model. Linear mixed-effects models were applied to assess the association between PM 2 . 5 exposure and changes in eGFR, adjusting for demographic, socioeconomic, and lifestyle covariates. Results: Each 1 µ g/m 3 higher lag 0–1 year PM 2 . 5 was associated with a −0.09 ml/min per 1.73 m 2 change in eGFR (95% confidence interval [CI], −0.16 to −0.01). More evident associations were observed among younger adults (−0.26; 95% CI, −0.42 to −0.09), individuals with preserved baseline kidney function (−0.14; 95% CI, −0.21 to −0.07), male (−0.10; 95% CI, −0.21 to 0), and individuals who were not prescribed tolvaptan (−0.12; 95% CI, −0.20 to −0.04). Conclusions: Chronic exposure to PM 2 . 5 appears to be an environmental modifier of kidney function decline in PKD, particularly among younger individuals and those with preserved kidney function. Environmental risk reduction strategies, together with pharmacologic therapy, may help delay the onset of ESKD in this vulnerable population.Keywords
Funding Information
- This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (No. 2022R1A2C2092353)
- Institute for Basic Science (IBS), Republic of Korea (IBS-R028-D1)
This publication has 22 references indexed in Scilit:
- MPs Entering Human Circulation through Infusions: A Significant Pathway and Health ConcernEnvironment & Health, 2025
- US Renal Data System 2022 Annual Data Report: Epidemiology of Kidney Disease in the United StatesAmerican Journal of Kidney Diseases, 2023
- High-Resolution Spatiotemporal Modeling for Ambient PM2.5 Exposure Assessment in China from 2013 to 2019Environmental Science & Technology, 2021
- Environmental pollution and kidney diseasesNature Reviews Nephrology, 2018
- Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015The Lancet, 2017
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration RateJAMA, 2012
- Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk PredictionsAmerican Journal of Kidney Diseases, 2010
- Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2008
- Autosomal dominant polycystic kidney diseaseThe Lancet, 2007